We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Trevena (TRVN) to Begin Clinical Study on Pain Candidate
Read MoreHide Full Article
Trevena, Inc. (TRVN - Free Report) announced that it is advancing its novel S1P receptor modulator, TRV045 into clinical development as a potential treatment for diabetic neuropathic pain (DNP). The company decided to begin clinical studies on TRV045 after it received a notification from the FDA that the study may proceed.
The company will initiate a three-part double-blind, placebo-controlled phase I study, which will evaluate the safety and tolerability of TRV045 in healthy adults. The study will also investigate the pharmacokinetics (PK) of TRV045 and determine whether the candidate is related to changes in lymphocyte counts, hemodynamic function, and QTcF interval.
The company plans to begin enrollment in the study early in the first quarter of 2022.
Per the company, part 1 of the study will evaluate single ascending doses of TRV045 or placebo while part 2 will evaluate the effect of a high-fat meal on the safety, tolerability, and relative bioavailability of TRV045. Part 3 will investigate multiple doses of TRV045 or placebo in up to three cohorts in order to obtain safety, tolerability, and PK data under multiple-dosing conditions.
Shares of Trevena have declined 67.5% so far this year compared with the industry’s decrease of 22.8%.
Image Source: Zacks Investment Research
We remind investors that in September 2021, the company had submitted an investigational new drug (IND) application for TRV045 to begin clinical studies on the same. However, the FDA issued a clinical hold letter regarding certain phase I study design elements. Trevena responded to the regulatory body’s comments and refiled the IND for TRV045 to treat DNP.
The company is also looking to study TRV045 as a potential treatment for epilepsy.
Please note that Trevena’s sole marketed product Olinvyk (oliceridine) injection is approved in the United States for the management of acute pain in adults severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
The company also has a portfolio of novel pipeline candidates, which are being developed for various types of central nervous system disorders. Apart from TRV045, Trevena is developing TRV250 for the acute treatment of migraine, TRV734 for moderate-to-severe acute and chronic pain as well as opioid use disorders and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19 infection.
Image: Bigstock
Trevena (TRVN) to Begin Clinical Study on Pain Candidate
Trevena, Inc. (TRVN - Free Report) announced that it is advancing its novel S1P receptor modulator, TRV045 into clinical development as a potential treatment for diabetic neuropathic pain (DNP). The company decided to begin clinical studies on TRV045 after it received a notification from the FDA that the study may proceed.
The company will initiate a three-part double-blind, placebo-controlled phase I study, which will evaluate the safety and tolerability of TRV045 in healthy adults. The study will also investigate the pharmacokinetics (PK) of TRV045 and determine whether the candidate is related to changes in lymphocyte counts, hemodynamic function, and QTcF interval.
The company plans to begin enrollment in the study early in the first quarter of 2022.
Per the company, part 1 of the study will evaluate single ascending doses of TRV045 or placebo while part 2 will evaluate the effect of a high-fat meal on the safety, tolerability, and relative bioavailability of TRV045. Part 3 will investigate multiple doses of TRV045 or placebo in up to three cohorts in order to obtain safety, tolerability, and PK data under multiple-dosing conditions.
Shares of Trevena have declined 67.5% so far this year compared with the industry’s decrease of 22.8%.
We remind investors that in September 2021, the company had submitted an investigational new drug (IND) application for TRV045 to begin clinical studies on the same. However, the FDA issued a clinical hold letter regarding certain phase I study design elements. Trevena responded to the regulatory body’s comments and refiled the IND for TRV045 to treat DNP.
The company is also looking to study TRV045 as a potential treatment for epilepsy.
Please note that Trevena’s sole marketed product Olinvyk (oliceridine) injection is approved in the United States for the management of acute pain in adults severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
The company also has a portfolio of novel pipeline candidates, which are being developed for various types of central nervous system disorders. Apart from TRV045, Trevena is developing TRV250 for the acute treatment of migraine, TRV734 for moderate-to-severe acute and chronic pain as well as opioid use disorders and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19 infection.
Zacks Rank & Stocks to Consider
Trevena currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Sarepta Therapeutics, Inc. (SRPT - Free Report) , Editas Medicine, Inc. (EDIT - Free Report) and vTv Therapeutics Inc. (VTVT - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Sarepta Therapeutics have narrowed 31.3% for 2021 and 26% for 2022 over the past 60 days.
Earnings of Sarepta Therapeutics surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.
Loss per share estimates for Editas Medicine have narrowed 11.2% for 2021 and 4.6% for 2022 over the past 60 days.
Editas Medicine’s earnings surpassed estimates in two of the trailing four quarters and missed the same on two occasions.
Loss per share estimates for vTv Therapeutics have narrowed 21.7% for 2021 and 2.9% for 2022 over the past 60 days.
vTv Therapeutics’ earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.